|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of biliary complications after orthotopic liver transplantation:The role of endoscopy显示文摘Biliary complications are signifi cant causes of morbidity and mortality after orthotopic liver transplantation (OLT). The estimated incidence of biliary complications after OLT ranges between 10%-25%,however,these numbers continue to decline due to improvement in surgical techniques. The most common biliary complications are strictures (both anastomotic and non-anastomotic) and bile leaks. Most of these problems can be appropriately managed with endoscopic retrograde colangiography (ERC). Other complications such as bile duct stones,bile casts,sphincter of Oddi dysfunction,and hemobilia,are less frequent and also can be managed with ERC. This article will review the risk factors,diagnosis,and endoscopic management of the most common biliary complications after OLT. | Maria C Londoo Domingo Balderramo Andrés Cárdenas | 2008 | World Journal of Gastroenterology2008，14，4： | 22 |
| 2 | Current management of biliary complications after liver transplantation: Emphasis on endoscopic therapy显示文摘 | Domingo Balderramo Miguel Navasa Andres Cardenas | 2010 | Gastroenterologia y Hepatologia2010，，2： | 2 |
| 3 | Hemolymphangioma of the pancreas:case report and review of the literature显示文摘 | Balderramo DC Di Tada C de Ditter AB | 2003 | Pancreas2003，27，2： | 1 |
| 4 | Hemolymphangioma of the pancreas: case report and review of the literature 显示文摘 | Balderramo D C Di-Tada C de-Ditter A B | 2003 | Pancreas2003，27，2： | 1 |
| 5 | Risk factors and outcomes of failed endoscopic retrograde cholangiopancreatography in liver transplant recipients with anastomotic biliary strictures:a case-control study显示文摘 | Balderramo D Sendino O Burrel M | | 0，，： | 1 |
| 6 | Hemolymphangioma of the pancreas: case report and review of the literature显示文摘 | Balderramo D C Di-Tada C de-Ditter A B | 2003 | Panereas2003，27，2： | 1 |
| 7 | Risk factors and out- comes of failed endoscopic retrograde cholangiopancreatography in liver transplant recipients with anastomotic biliary strictures: a case-control study显示文摘 | Balderramo D Sendino O Bun'el M | 2012 | Liver Transpl2012，18，4： | 1 |
| 8 | Current impact of viral hepatitis on liver cancer development: The challenge remains显示文摘Chronic infections due to hepatitis B and hepatitis C viruses are responsible for most cases of hepatocellular carcinoma(HCC)worldwide,and this association is likely to remain during the next decade.Moreover,viral hepatitis-related HCC imposes an important burden on public health in terms of disability-adjusted life years.In order to reduce such a burden,some major challenges must be faced.Universal vaccination against hepatitis B virus,especially in the neonatal period,is probably the most relevant primary preventive measure against the development of HCC.Moreover,considering the large adult population already infected with hepatitis B and C viruses,it is also imperative to identify these individuals to ensure their access to treatment.Both hepatitis B and C currently have highly effective therapies,which are able to diminish the risk of development of liver cancer.Finally,it is essential for individuals at high-risk of HCC to be included in surveillance programs,so that tumors are detected at an early stage.Patients with hepatitis B or C and advanced liver fibrosis or cirrhosis benefit from being followed in a surveillance program.As hepatitis B virus is oncogenic and capable of leading to liver cancer even in individuals with early stages of liver fibrosis,other high-risk groups of patients with hepatitis B are also candidates for surveillance.Considerable effort is required concerning these strategies in order to decrease the incidence and the mortality of viral hepatitis-related HCC. | Ângelo Zambam de Mattos Jose D Debes Andre Boonstra Ju-Dong Yang Domingo C Balderramo Giovana D P Sartori Angelo Alves de Mattos | 2021 | World Journal of Gastroenterology2021，27，24： | 1 |
| 9 | Prospective Evaluation of Single‐Operator Peroral Cholangioscopy in Liver Transplant Recipients Requiring an Evaluation of the Biliary Tract显示文摘 | Domingo Balderramo Oriol Sendino Rosa Miquel Cristina Rodriguez de Miguel Josep M. Bordas Graciela Martinez‐Palli Maria L. Leoz Antoni Rimola Miguel Navasa Josep Llach Andrés Cardenas | 2013 | Liver Transpl2013，，2： | 1 |
| 10 | Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease显示文摘Inflammatory bowel disease(IBD)is a group of chronic diseases that includes ulcerative colitis,Crohn’s disease,and indeterminate colitis.Patients with IBD require prolonged treatment and high utilization of healthcare resources for proper management.The treatment of patients with IBD is focused on achieving therapeutic goals including clinical,biochemical,and endoscopic variables that result in improvement of the quality of life and prevention of disability.Advanced IBD treatment includes tumor necrosis factor inhibitors,integrin antagonist,antagonist of the p40 subunit of interleukin 12/23,and small molecule drugs.However,despite the multiple treatments available,about 40%of patients are refractory to therapy and present with persistent symptoms that have a great impact on their quality of life,with hospitalization and surgery being necessary in many cases.Dual therapy,a strategy sometimes applicable to refractory IBD patients,includes the combination of two biologics or a biologic in combination with a small molecule drug.There are two distinct scenarios in IBD patients in which this approach can be used:(1)Refractory active luminal disease without extraintestinal manifestations;and(2)patients with IBD in remission,but with active extraintestinal manifestations or immune-mediated inflammatory diseases.This review provides a summary of the results(clinical response and remission)of different combinations of advanced drugs in patients with IBD,both in adults and in the pediatric population.In addition,the safety profile of different combinations of dual therapy is analyzed.The use of newer combinations,including recently approved treatments,the application of new biomarkers and artificial intelligence,and clinical trials to establish effectiveness during long-term followup,are needed to establish new strategies for the use of advanced treatments in patients with refractory IBD. | Domingo Balderramo | 2022 | World Journal of Gastroenterology2022，28，47： | 1 |
| 11 | Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation显示文摘 | Cervera C Balderramo D Suorez B | | 0，，10： | 1 |
| 12 | Primary osteoporosis risk factors in women from Cordoba显示文摘 | Balderramo DC Ramacciotti CF Douthat WG | 2004 | Argentina Medicina(B Aires)2004，64，5： | 1 |
| 13 | Primary osteoporosis risk factors in women from Cordoba 显示文摘 | Balderramo DC Ramacciotti CF Douthat WG | 2004 | Argentina Medicina ( B Aires )2004，64，5： | 1 |
| 14 | Current management of biliary complications after liver transplantation: Emphasis on endoscopic therapy显示文摘 | Balderramo D Navasa M Cardenas A | 2011 | Gastroenterol Hepatol2011，34，： | 1 |
| 15 | Primary osteoporosis risk factors in women from Cordoba显示文摘 | Balderramo DC Ramacciotti CF Douthat WG | 2004 | Argentina Medicina(BAires)2004，64，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员